Skip to main content
Journal cover image

Prediction of one-year mortality among 30-day survivors after primary percutaneous coronary interventions.

Publication ,  Journal Article
Mehta, RH; O'neill, WW; Harjai, KJ; Cox, DA; Brodie, BR; Boura, J; Grines, L; Stone, GW; Grines, CL ...
Published in: Am J Cardiol
March 15, 2006

Little information exists on the features that influence risk factors for death at 1 year among 30-day survivors of ST-elevation myocardial infarction (STEMI) that is treated with primary percutaneous coronary intervention (PCI). Accordingly, we examined 3,280 patients with STEMI who were enrolled in Stent-PAMI and CADILLAC trials, were treated with primary PCI, and survived >30 days after STEMI. Death at 1 year occurred in 74 patients (2.3%) who survived >30 days after their index STEMI. Patients who died at 1 year were more likely to be older and women and have lower body weight and greater prevalence of previous stroke. Similarly, the sum of ST elevations, 3-vessel or left anterior coronary disease, and final Thrombolysis In Myocardial Infarction grade <3 flow was higher, whereas left ventricular ejection fraction was lower among patients who died versus those who survived. The multivariate logistic regression model identified age >70 years (odds ratio [OR] 3.3 95% confidence interval [CI] 1.9 to 5.7), weight <80 kg (OR 1.9, 95% CI 1.1 to 3.6), any tachyarrhythmia during index hospitalization (defined as ventricular or supraventricular tachycardia that required treatment) (OR 2.4, 95% CI 1.2 to 4.8), number of diseased coronary arteries (OR 1.5, 95% CI 1.1 to 2.1), and left ventricular ejection fraction (each 10% decrease, OR 1.5, 95% CI 1.2 to 1.8) as factors independently associated with risk of death at 1 year among 30-day survivors. In conclusion, our study provides a method for clinicians to advise patients who are treated with primary PCI and survive the acute phase of STEMI with regard to patients' long-term prognosis, thus enhancing planning and setting up of realistic expectations.

Duke Scholars

Published In

Am J Cardiol

DOI

ISSN

0002-9149

Publication Date

March 15, 2006

Volume

97

Issue

6

Start / End Page

817 / 822

Location

United States

Related Subject Headings

  • Survival Analysis
  • Stents
  • Randomized Controlled Trials as Topic
  • Predictive Value of Tests
  • Platelet Aggregation Inhibitors
  • Myocardial Infarction
  • Middle Aged
  • Male
  • Logistic Models
  • Immunoglobulin Fab Fragments
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mehta, R. H., O’neill, W. W., Harjai, K. J., Cox, D. A., Brodie, B. R., Boura, J., … Primary Angioplasty in Myocardial Infarction (PAMI) and the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. (2006). Prediction of one-year mortality among 30-day survivors after primary percutaneous coronary interventions. Am J Cardiol, 97(6), 817–822. https://doi.org/10.1016/j.amjcard.2005.09.131
Mehta, Rajendra H., William W. O’neill, Kishore J. Harjai, David A. Cox, Bruce R. Brodie, Judy Boura, Lorelei Grines, Gregg W. Stone, Cindy L. Grines, and Primary Angioplasty in Myocardial Infarction (PAMI) and the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. “Prediction of one-year mortality among 30-day survivors after primary percutaneous coronary interventions.Am J Cardiol 97, no. 6 (March 15, 2006): 817–22. https://doi.org/10.1016/j.amjcard.2005.09.131.
Mehta RH, O’neill WW, Harjai KJ, Cox DA, Brodie BR, Boura J, et al. Prediction of one-year mortality among 30-day survivors after primary percutaneous coronary interventions. Am J Cardiol. 2006 Mar 15;97(6):817–22.
Mehta, Rajendra H., et al. “Prediction of one-year mortality among 30-day survivors after primary percutaneous coronary interventions.Am J Cardiol, vol. 97, no. 6, Mar. 2006, pp. 817–22. Pubmed, doi:10.1016/j.amjcard.2005.09.131.
Mehta RH, O’neill WW, Harjai KJ, Cox DA, Brodie BR, Boura J, Grines L, Stone GW, Grines CL, Primary Angioplasty in Myocardial Infarction (PAMI) and the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Prediction of one-year mortality among 30-day survivors after primary percutaneous coronary interventions. Am J Cardiol. 2006 Mar 15;97(6):817–822.
Journal cover image

Published In

Am J Cardiol

DOI

ISSN

0002-9149

Publication Date

March 15, 2006

Volume

97

Issue

6

Start / End Page

817 / 822

Location

United States

Related Subject Headings

  • Survival Analysis
  • Stents
  • Randomized Controlled Trials as Topic
  • Predictive Value of Tests
  • Platelet Aggregation Inhibitors
  • Myocardial Infarction
  • Middle Aged
  • Male
  • Logistic Models
  • Immunoglobulin Fab Fragments